Physicians' Academy for Cardiovascular Education

No definite difference for primary endpoint but proven safety with ARNI in MI patients

5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

A novel simplified algorithm to achieve LDL-c goal in very-high risk patients

15' education - May 11, 2021 - Prof. Luis Masana, MD, PhD and prof. Erik Stroes, MD, PhD

A new approach with LLT for very-high and extremely-high risk patients

5' education - May 6, 2021 - Prof. Maciej Banach, PhD, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Lipid-lowering therapies for statin-intolerant patients

15' education - May 5, 2021 - Prof. Maciej Banach, MD, PhD and prof. Ulrich Laufs, MD, PhD

Treatment algorithms for HFpEF

10' education - May 4, 2021 - Prof. John Cleland, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Solutions for improving LDL-c goal attainment - changing treatment patterns

15' education - Apr. 28, 2021 - Prof. Ulrich Laufs, MD, PhD and Derek Connolly, MD, PhD - Online CME

Recommendations for treatment algorithm of HFrEF

10' education - Apr. 26, 2021 - Andrew Coats, MD

PCSK9 inhibition in clinical practice

5' education - Apr. 21, 2021 - Prof. Maciej Banach, PhD, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Solutions for improving LDL-c goal attainment - advances in patient selection

15' education - Apr. 20, 2021 - Prof. Maciej Banach, MD, PhD, and prof. John Kastelein, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

What are current challenges and barriers in achieving LDL-c goals?

15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME

Outcomes with P2Y12 inhibitors after PCI according to CYP2C19 genotype

5' education - Apr. 12, 2021 - Danny Claassens, MD

Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin

5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: how are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME

Clinical outcomes with low dose vs. high dose DOAC in AF

5' education - Mar. 30, 2021 - Prof. Jan Steffel, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

The proven case for LDL-c lowering

15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Personalized antithrombotic therapy after PCI

5' education - Mar. 17, 2021 - Niels van der Sangen, MD

Ketones as a possible therapeutic option for patients with CVD

10' education - Mar. 16, 2021 - B. Daan Westenbrink MD, PhD

ARNI does not significantly decrease CV death, HF hospitalization or outpatient HF in MI patients

News - May 15, 2021

ACC 2021 In the PARADISE-MI trial, treatment with sacubitril/valsartan resulted in a non-significant 10% decrease in the primary outcome compared to ramipril in high risk acute MI patients.

No definite difference for primary endpoint but proven safety with ARNI in MI patients

5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD
A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to rampitril in MI patients is provided by prof. Pfeffer.

ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to rampitril in MI patients is provided by prof. Pfeffer.

Sustained CV benefits of statin treatment after discontinuation

Literature - May 12, 2021 - Bosch J et al. - Eur Heart J. 2021

CV benefits of rosuvastatin, compared with placebo, are sustained or enhanced even after stopping therapy in individuals without CVD but at intermediate risk for CV events.

Primary endpoint met in CV outcome trial with nonsteroidal MRA in patients with DKD

News - May 11, 2021

In the FIGARO-DKD phase 3 trial, the nonsteroidal MRA finerenone reduced the primary endpoint, a composite of CV death and non-fatal CV events, compared to placebo in patients with CKD and T2DM.

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD
Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.

Prof. Januzzi talks about the biology of natriuretic peptides and discusses their performance in patients with kidney disfunction for diagnosis and prognosis of HF.

A novel simplified algorithm to achieve LDL-c goal in very-high risk patients

15' education - May 11, 2021 - Prof. Luis Masana, MD, PhD and prof. Erik Stroes, MD, PhD
The approach of upfront combination therapy in very-high risk patients is easier for physicians and a big win for patients, according to prof. Stroes and prof. Masana.

Experts in dialogue The approach of upfront combination therapy in very-high risk patients is easier for physicians and a big win for patients, according to prof. Stroes and prof. Masana.

Update of EHRA practical guide on use of NOACs in AF

News - May 10, 2021

The European Heart Rhythm Association has released the 2021 update of the practical guide on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in AF patients.

Higher mortality among MI patients with atypical symptoms

Literature - May 10, 2021 - Lykkemark Møller A et al. - Eur Heart J Acute Cardiovasc Care. 2021

MI patients with atypical symptoms had a lower chance of receiving an emergency dispatch, and higher 30-day mortality compared to MI patients with chest pain. Breathing problems was the most common atypical symptom.

More research needed for optimal hypertension screening and confirmatory algorithms

Literature - May 10, 2021 - Guirguis-Blake J, et al. - JAMA 2021

This systematic review for the US Preventive Services Task Force provides an overview of benefits and harms of screening for hypertension in adults and on the accuracy of screening and confirmatory BP measurements.

A new approach with LLT for very-high and extremely-high risk patients

5' education - May 6, 2021 - Prof. Maciej Banach, PhD, MD
Based on a recent position paper endorsed by the International Lipid Expert Panel, prof. Banach discusses pathways of optimal lipid-lowering therapy in very-high and extremely-high risk patients.

Based on a recent position paper endorsed by the International Lipid Expert Panel, prof. Banach discusses pathways of optimal lipid-lowering therapy in very-high and extremely-high risk patients.

Elevated markers of atherosclerosis and lower carotid distensibility associated with dementia

Literature - May 5, 2021 - Wang W et al. - J Am Heart Assoc. 2021

This analysis in a community-based cohort showed that elevated carotid intima-media thickness and interadventitial diameter and lower carotid distensibility were associated with increased risk of incident dementia.

Consistent effect of SGLT2i on CV outcomes across eGFR and UACR groups in T2DM

Literature - May 5, 2021 - Zelniker TA, et al. - JAMA Cardiol 2021

Relative risk reductions by dapagliflozin on CV outcomes were irrespective of baseline eGFR and albuminuria status in T2DM patients who had or were at risk of ASCV, shown in a secondary analysis of DECLARE-TIMI 58.